SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77641.05
875.13 (1.14%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Biocon Ltd.	Q V PT	70,452 Mid Cap	431.25 (-0.24%)	1893.86	2.58	2.96	-18.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Jubilant Pharmova Ltd.	Q V+ PT	15,366 Small Cap	980 (1.59%)	772.15	6.65	-24.99	-38.93	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Healthcare Global Enterprises Ltd.	Q V+ PT	10,135 Small Cap	673 (-0.86%)	695.16	6.32	13.15	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Onesource Specialty Pharma Ltd.	Q V PT	19,809 Small Cap	1,735.20 (0.45%)	415.98	3.3	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Senores Pharmaceuticals Ltd.	Q V+ PT	6,108 Small Cap	1,332.80 (0.49%)	328.57	8.13	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Park Medi World Ltd.	Q V+ PT	11,997 Small Cap	279.35 (0.58%)	327.64	13.95	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Fortis Healthcare Ltd.	Q V+ PT	71,393 Mid Cap	954.30 (0.91%)	309.94	7.74	23.15	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Aster DM Quality Care Ltd.	Q V+ PT	70,919 Mid Cap	818 (0.54%)	182.72	14.39	-13.71	0.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	Wockhardt Ltd.	Q V+ PT	30,660 Small Cap	1,925.35 (2.04%)	143.94	6.22	4.49	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Rubicon Research Ltd.	Q V+ PT	25,392 Small Cap	1,522.30 (-0.76%)	134.94	18.76	32.49	25.95	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	Krishna Institute of Medical Sciences Ltd	Q V PT	33,489 Small Cap	796.10 (-0.16%)	128.46	8.52	11.87	17.04	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	Dr. Agarwals Health Care Ltd.	Q V PT	15,602 Small Cap	489.50 (-0.54%)	117.14	7.7	26.38	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Orchid Pharma Ltd.	Q V PT	4,999 Small Cap	996.45 (1.10%)	110.58	3.65	13.89	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Astrazeneca Pharma India Ltd.	Q V PT	20,174 Small Cap	8,189.70 (1.49%)	107.58	23.29	22.84	15.69	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	Gujarat Kidney And Super Speciality Ltd.	Q V PT	1,001 Small Cap	127.20 (0.16%)	101.13	4.06	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	Akums Drugs & Pharmaceuticals Ltd.	Q V PT	10,416 Small Cap	658.10 (-0.55%)	93.3	4.29	10.00	11.58	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	Cohance Lifesciences Ltd.	Q V+ PT	16,299 Small Cap	429.30 (0.77%)	90.94	4.17	7.51	-3.15	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	Laurus Labs Ltd.	Q V+ PT	94,987 Mid Cap	1,782.40 (1.39%)	86.88	16.84	7.19	-2.25	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Torrent Pharmaceuticals Ltd.	Q V+ PT	1,86,354 Large Cap	4,882 (-0.35%)	86.14	22.16	11.80	13.74	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Apollo Hospitals Enterprise Ltd.	Q V+ PT	1,28,055 Large Cap	8,955.45 (0.55%)	85.79	12.85	-3.49	29.94	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
21	Yatharth Hospital & Trauma Care Services Ltd.	Q V PT	8,034 Small Cap	836.20 (0.29%)	84.21	4.96	27.90	137.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
22	Gujarat Themis Biosyn Ltd.	Q V+ PT	3,878 Small Cap	357 (0.32%)	83.06	13.47	12.12	15.55	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
23	Vijaya Diagnostic Centre Ltd.	Q V PT	13,987 Small Cap	1,361.25 (0.24%)	80.86	14.61	15.00	18.43	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
24	Sai Life Sciences Ltd.	Q V+ PT	27,605 Small Cap	1,309.25 (0.69%)	80.84	11.01	17.75	11.20	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
25	Divis Laboratories Ltd.	Q V+ PT	1,96,990 Large Cap	7,781.20 (4.86%)	76.71	11.75	8.67	4.44	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
26	Global Health Ltd.	Q V PT	37,590 Small Cap	1,429 (2.21%)	75.75	9.35	16.83	34.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
27	Max Healthcare Institute Ltd.	Q V+ PT	1,07,532 Mid Cap	1,114.20 (0.85%)	74.55	10.14	27.27	155.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
28	Tarsons Products Ltd.	Q V PT	1,655 Small Cap	319.35 (2.67%)	73.04	2.45	12.30	-1.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
29	Laxmi Dental Ltd.	Q V PT	1,181 Small Cap	215.75 (0.44%)	71.87	4.78	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
30	Anthem Biosciences Ltd.	Q V PT	44,169 Mid Cap	786.65 (0.34%)	70.76	13.58	13.62	19.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Artemis MedicareServ	300.90	8.55%
Suven Life Sciences	309.10	5.05%
Divis Laboratories	7,781.20	4.86%
SMS Pharmaceuticals	397.50	4.36%
Dr. Lal Pathlabs	1,881.75	4.18%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Hester Biosciences	2,460.10	-2.57%
Fischer Medical	35.99	-2.31%
3B Blackbio Dx	1,275	-1.63%
Fermenta Biotech	450	-1.37%
Indraprastha Medical	363.50	-1.29%

News about Top Pharma Companies in India

Jul, 2026

AstraZeneca Pharma India informs about certificate

AstraZeneca Pharma India has informed that it enclosed the Certificate dated July 27, 2026 issued by Integrated Registry Management Services, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Biocon informs about company statement

Biocon has informed that it enclosed Company Statement with respect to ‘Biocon Receives Health Canada Approval for Yesintek® (ustekinumab) Autoinjector Pen’. The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Senores Pharmaceutic - Quaterly Results

The turnover zoomed to Rs. 269.90 millions, up 67.33% for the June 2026 quarter as against Rs. 161.30 millions during the year-ago period.Net Profit of the company move down -61.85% to Rs. 10.30 millions from Rs. 27.00 millions in the same quarter last year.The company reported a degrowth in operating Profit to 72.20 millions from 72.30 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	269.90	161.30	67.33	269.90	161.30	67.33	1060.90	385.40	175.27
Other Income	95.50	120.80	-20.94	95.50	120.80	-20.94	663.50	219.90	201.73
PBIDT	72.20	72.30	-0.14	72.20	72.30	-0.14	476.70	147.10	224.07
Interest	22.20	17.60	26.14	22.20	17.60	26.14	69.80	65.20	7.06
PBDT	50.00	54.70	-8.59	50.00	54.70	-8.59	406.90	81.90	396.83
Depreciation	36.10	18.80	92.02	36.10	18.80	92.02	132.30	30.80	329.55
PBT	13.90	35.90	-61.28	13.90	35.90	-61.28	274.60	51.10	437.38
TAX	3.60	8.90	-59.55	3.60	8.90	-59.55	72.10	14.20	407.75
Deferred Tax	0.50	5.00	-90.00	0.50	5.00	-90.00	-12.40	-0.30	4033.33
PAT	10.30	27.00	-61.85	10.30	27.00	-61.85	202.50	36.90	448.78
Equity	460.54	460.54	0.00	460.54	460.54	0.00	460.50	460.50	0.00
PBIDTM(%)	26.75	44.82	-40.32	26.75	44.82	-40.32	44.93	38.17	17.73

Jul, 2026

Anthem Biosciences informs about transcript of conference call

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Anthem Biosciences has informed that it enclosed the transcript of the earnings conference call held on July 22, 2026, at 11:30 AM, post announcement of Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. The said transcript is also available on website of the Company at https://anthembio.com/.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Laurus Labs - Quaterly Results

The company witnessed a 22.64% growth in the revenue at Rs. 17571.60 millions for the quarter ended June 2026 as compared to Rs. 14327.50 millions during the year-ago period.Profit for the quarter ended June 2026 rises by 83.59% to Rs. 2899.60 millions from Rs. 1579.40 millions.Operating profit for the quarter ended June 2026 rose to 5191.30 millions as compared to 3489.00 millions of corresponding quarter ended June 2025.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	17571.60	14327.50	22.64	17571.60	14327.50	22.64	60890.70	52169.80	16.72
Other Income	200.70	215.20	-6.74	200.70	215.20	-6.74	774.30	1004.70	-22.93
PBIDT	5191.30	3489.00	48.79	5191.30	3489.00	48.79	15156.90	10448.00	45.07
Interest	352.00	438.90	-19.80	352.00	438.90	-19.80	1429.60	1822.00	-21.54
PBDT	4839.30	3050.10	58.66	4839.30	3050.10	58.66	13727.30	8626.00	59.14
Depreciation	957.60	935.70	2.34	957.60	935.70	2.34	3786.40	3587.90	5.53
PBT	3881.70	2114.40	83.58	3881.70	2114.40	83.58	9940.90	5038.10	97.31
TAX	982.10	535.00	83.57	982.10	535.00	83.57	2536.10	1234.20	105.49
Deferred Tax	-50.40	-61.60	-18.18	-50.40	-61.60	-18.18	-315.10	-304.20	3.58
PAT	2899.60	1579.40	83.59	2899.60	1579.40	83.59	7404.80	3803.90	94.66
Equity	1080.50	1079.60	0.08	1080.50	1079.60	0.08	1079.70	1078.50	0.11
PBIDTM(%)	29.54	24.35	21.32	29.54	24.35	21.32	24.89	20.03	24.29

Jul, 2026

Onesource Specialty - Quaterly Results

A decent increase of about 39.08% in the sales to Rs. 4464.71 millions was observed for the quarter ended June 2026. The sales figure stood at Rs. 3210.12 millions during the year-ago period.The company almost doubled its revenue to Rs. 512.25 millions from Rs. 248.15 millions in the quarter ended June 2026.Operating Profit saw a handsome growth to 1179.19 millions from 851.30 millions in the quarter ended June 2026.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	4464.71	3210.12	39.08	4464.71	3210.12	39.08	14053.81	12995.89	8.14
Other Income	37.87	52.55	-27.94	37.87	52.55	-27.94	150.08	176.82	-15.12
PBIDT	1179.19	851.30	38.52	1179.19	851.30	38.52	2840.01	3869.57	-26.61
Interest	305.17	270.31	12.90	305.17	270.31	12.90	1205.76	1616.50	-25.41
PBDT	874.02	580.99	50.44	874.02	580.99	50.44	1580.05	1130.57	39.76
Depreciation	361.77	332.84	8.69	361.77	332.84	8.69	1367.95	1345.12	1.70
PBT	512.25	248.15	106.43	512.25	248.15	106.43	212.10	-214.55	-198.86
TAX	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-414.55	0.00
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-414.55	0.00
PAT	512.25	248.15	106.43	512.25	248.15	106.43	212.10	200.00	6.05
Equity	114.64	114.46	0.16	114.64	114.46	0.16	114.62	114.43	0.17
PBIDTM(%)	26.41	26.52	-0.41	26.41	26.52	-0.41	20.21	29.78	-32.13

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Biocon Ltd.	70,452 Crore
2	Jubilant Pharmova Ltd.	15,366 Crore
3	Healthcare Global Enterprises Ltd.	10,135 Crore
4	Onesource Specialty Pharma Ltd.	19,809 Crore
5	Senores Pharmaceuticals Ltd.	6,108 Crore
6	Park Medi World Ltd.	11,997 Crore
7	Fortis Healthcare Ltd.	71,393 Crore
8	Aster DM Quality Care Ltd.	70,919 Crore
9	Wockhardt Ltd.	30,660 Crore
10	Rubicon Research Ltd.	25,392 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,769	59,301	38.21	12.49	26.17	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,882	1,86,354	86.14	22.16	44.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,459	1,09,494	20.53	4.89	11.88	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,382	41,675	39.47	9.21	26.67	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,668	67,559	30.92	4.83	22.42	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,782	94,987	97.82
Sai Life Sciences Ltd. (S)	Very Good	1,309	27,605	57.56
Aurobindo Pharma Ltd. (M)	Very Good	1,591	89,212	37.52
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,882	1,86,354	35.15
Lupin Ltd. (M)	Somewhat Good	2,459	1,09,494	22.15
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,309	27,605	80.84	11.01	42.51	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,382	41,675	39.47	9.21	26.67	13.54
Mankind Pharma Ltd. (M)	Very Good	2,605	1,08,129	53.07	6.61	33.20	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,124	1,09,686	21.76	4.22	13.36	13.52
Lupin Ltd. (M)	Somewhat Good	2,459	1,09,494	20.53	4.89	11.88	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,459	1,09,494	20.53	4.89	11.88	32.37
Abbott India Ltd. (M)	Very Good	27,769	59,301	38.21	12.49	26.17	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,144	94,790	29.42	2.48	15.11	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,124	1,09,686	21.76	4.22	13.36	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,982	4,74,397	41.33	5.68	23.70	14.41

You have 7 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

AstraZeneca Pharma India informs about certificate

Biocon informs about company statement

Senores Pharmaceutic - Quaterly Results

Anthem Biosciences informs about transcript of conference call

Laurus Labs - Quaterly Results

Onesource Specialty - Quaterly Results

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.